Denis Damião Costa1, Carlos Brites2,3, Sara Nunes Vaz3, Daniele Souza de Santana3, Jean Nunes Dos Santos1,4, Patricia Ramos Cury1,5. 1. Postgraduate Program in Dentistry and Health, Federal University of Bahia, Salvador, Brazil. 2. Infectious Diseases Research Laboratory, Professor Edgard Santos Hospital, Federal University of Bahia, Salvador, Brazil. 3. Postgraduate Program in Medicine and Health, Federal University of Bahia, Salvador, Brazil. 4. Department of Oral Pathology, School of Dentistry, Federal University of Bahia, Salvador, Brazil. 5. Department of Periodontology, School of Dentistry, Federal University of Bahia, Salvador, Brazil.
Abstract
OBJECTIVES: This study aimed to evaluate the effect of 0.12% chlorhexidine gluconate on the salivary load of SARS-CoV-2. MATERIALS AND METHODS: A randomized, double-blind, placebo-controlled trial was performed on 100 participants positive for SARS-CoV-2. In the test group (n = 50), volunteers gargled with a mouthwash containing 15 ml of 0.12% chlorhexidine gluconate for 1 min, while the control group (n = 50) used a placebo. Saliva samples were obtained before (baseline) and 5 and 60 min after using the solutions. Real-time reverse transcription polymerase chain reaction assays (qRT-PCR) were carried out and the cycle threshold (Ct) was computed. The chi-square test and t-test were used for group comparison (p ≤ 0.05). RESULTS: The differences in Ct values between the 5-min evaluation and baseline (test group: 2.19 ± 4.30; control: -0.40 ± 3.87, p = 0.002) and between 60 min and baseline (test group: 2.45 ± 3.88; control: 0.76 ± 4.41, p = 0.05) were significantly greater in the test group, revealing a reduction of viral load. Furthermore, there was a reduction in the load of SARS-CoV-2 in 72% of the volunteers using chlorhexidine versus 30% in the control group (p = 0.001). CONCLUSIONS: Chlorhexidine gluconate (0.12%) was effective in reducing salivary SARS-CoV-2 load for at least 60 min.
OBJECTIVES: This study aimed to evaluate the effect of 0.12% chlorhexidine gluconate on the salivary load of SARS-CoV-2. MATERIALS AND METHODS: A randomized, double-blind, placebo-controlled trial was performed on 100 participants positive for SARS-CoV-2. In the test group (n = 50), volunteers gargled with a mouthwash containing 15 ml of 0.12% chlorhexidine gluconate for 1 min, while the control group (n = 50) used a placebo. Saliva samples were obtained before (baseline) and 5 and 60 min after using the solutions. Real-time reverse transcription polymerase chain reaction assays (qRT-PCR) were carried out and the cycle threshold (Ct) was computed. The chi-square test and t-test were used for group comparison (p ≤ 0.05). RESULTS: The differences in Ct values between the 5-min evaluation and baseline (test group: 2.19 ± 4.30; control: -0.40 ± 3.87, p = 0.002) and between 60 min and baseline (test group: 2.45 ± 3.88; control: 0.76 ± 4.41, p = 0.05) were significantly greater in the test group, revealing a reduction of viral load. Furthermore, there was a reduction in the load of SARS-CoV-2 in 72% of the volunteers using chlorhexidine versus 30% in the control group (p = 0.001). CONCLUSIONS: Chlorhexidine gluconate (0.12%) was effective in reducing salivary SARS-CoV-2 load for at least 60 min.
Authors: Zack Saud; Victoria J Tyrrell; Andreas Zaragkoulias; Majd B Protty; Evelina Statkute; Anzelika Rubina; Kirsten Bentley; Daniel A White; Patricia Dos Santos Rodrigues; Robert C Murphy; Harald Köfeler; William J Griffiths; Jorge Alvarez-Jarreta; Richard William Brown; Robert G Newcombe; James Heyman; Manon Pritchard; Robert Wj Mcleod; Arvind Arya; Ceri-Ann Lynch; David Owens; P Vince Jenkins; Niklaas J Buurma; Valerie B O'Donnell; David W Thomas; Richard J Stanton Journal: J Lipid Res Date: 2022-04-15 Impact factor: 6.676
Authors: Álvaro Sánchez Barrueco; María Victoria Mateos-Moreno; Yolanda Martínez-Beneyto; Elisa García-Vázquez; Alfonso Campos González; Javier Zapardiel Ferrero; Abel Bogoya Castaño; Ignacio Alcalá Rueda; José Miguel Villacampa Aubá; Carlos Cenjor Español; Laura Moreno-Parrado; Verónica Ausina-Márquez; Sandra García-Esteban; Alejandro Artacho; F Xavier López-Labrador; Alex Mira; María D Ferrer Journal: Emerg Microbes Infect Date: 2022-12 Impact factor: 19.568
Authors: Majdy Idrees; Bridget McGowan; Amr Fawzy; Abdulwahab Ali Abuderman; Ramesh Balasubramaniam; Omar Kujan Journal: Int J Environ Res Public Health Date: 2022-09-25 Impact factor: 4.614
Authors: Alvaro Garcia-Sanchez; Juan-Francisco Peña-Cardelles; Steve Ruiz; Flor Robles; Esther Ordonez-Fernandez; Angel-Orión Salgado-Peralvo; James Balloch; Jacob C Simon Journal: J Clin Med Date: 2022-03-18 Impact factor: 4.241